Last reviewed · How we verify

NCT05066243

A Patient Reported Outcome Measure for Vulval Conditions

Status unknown Last updated 4 October 2021
What this trial tests

trial testing questionnaire in Vulval Dermatoses in 165 participants. Status unknown.

Timeline
9 October 2021
Primary endpoint
1 February 2022
15 April 2022

Quick facts

Lead sponsorLiverpool University Hospitals NHS Foundation Trust
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment165
Start date9 October 2021
Primary completion1 February 2022
Estimated completion15 April 2022

Drugs / interventions tested

Conditions studied

Sponsor

Liverpool University Hospitals NHS Foundation Trust

Who can join

18 and older, female only, with Vulval Dermatoses or Vulval Pain Syndromes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To create a new patient reported outcome measure in the form of a questionnaire, which will accurately reflect the profound impact that vulval dermatoses and vulval pain syndromes have on patients' quality of life

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of questionnaire

Trials testing the same drug.

Other Liverpool University Hospitals NHS Foundation Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05066243.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing